Dr. Charles M Farber, MD
Claim this profileMorristown Medical Center
Studies Lymphoma
Studies Non-Small Cell Lung Cancer
19 reported clinical trials
39 drugs studied
Area of expertise
1Lymphoma
Stage IV
Stage III
Stage I
2Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Charles M Farber, MD is currently running
Pembrolizumab + TKI
for Chronic Myeloid Leukemia
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
Recruiting1 award Phase 2
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
More about Charles M Farber, MD
Clinical Trial Related11 years of experience running clinical trials · Led 19 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Charles M Farber, MD has experience with
- Pembrolizumab
- Brentuximab Vedotin
- Pemetrexed
- Carboplatin
- Nivolumab
- Dacarbazine
Breakdown of trials Charles M Farber, MD has run
Lymphoma
Non-Small Cell Lung Cancer
Hodgkin's Lymphoma
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Charles M Farber, MD specialize in?
Charles M Farber, MD focuses on Lymphoma and Non-Small Cell Lung Cancer. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage III.
Is Charles M Farber, MD currently recruiting for clinical trials?
Yes, Charles M Farber, MD is currently recruiting for 6 clinical trials in Morristown New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Charles M Farber, MD has studied deeply?
Yes, Charles M Farber, MD has studied treatments such as Pembrolizumab, Brentuximab Vedotin, Pemetrexed.
What is the best way to schedule an appointment with Charles M Farber, MD?
Apply for one of the trials that Charles M Farber, MD is conducting.
What is the office address of Charles M Farber, MD?
The office of Charles M Farber, MD is located at: Morristown Medical Center, Morristown, New Jersey 07960 United States. This is the address for their practice at the Morristown Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.